Table 4 Risk factors analysis for RVO in KT group.

From: Impact of kidney transplantation on the risk of retinal vein occlusion in end-stage renal disease

Variables

Model 1

Model 2

Hazard ratio (95% CI)

P-value

Hazard ratio (95% CI)

P-value

Age, years

20–29

0.20 (0.74, 0.56)

 

0.48 (0.17, 1.36)

 

30–39

0.40 (0.24, 0.65)

 

0.84 (0.49, 1.43)

 

40–49

0.53 (0.36, 0.78)

 

1 (ref)

 

50–59

1 (ref)

< 0.001

1.79 (1.20, 2.66)

< 0.001

60–69

1.69 (1.08, 2.57)

 

2.98 (1.83, 4.85)

 

70–79

4.26 (1.34, 13.56)

 

7.89 (2.40, 5.99)

 

≥ 80

    

Sex

Male

1 (Ref.)

0.3145

1 (Ref.)

0.560

Female

0.85 (0.62, 1.17)

0.85 (0.62, 1.176)

DM

Yes

1.96 (1.44, 2.67)

< 0.001

1.2(0.86, 1.68)

0.243

No

1 (Ref.)

1 (Ref.)

HTN

Yes

1.23 (0.68, 2.21)

0.495

1.05 (0.58, 1.91)

0.846

No

1 (Ref.)

1 (Ref.)

Dyslipidemia

Yes

1.20 (0.88, 1.643)

0.255

1.04 (0.75, 1.43)

0.820

No

1 (Ref.)

1 (Ref.)

CCI score

0

 

< 0.001

 

0.005

1–2

1 (Ref.)

1 (Ref.)

3–4

1.56 (0.69, 3.51)

1.36 (0.60, 3.08)

 ≥ 5

3.71 (1.73, 7.94)

2.57 (1.17, 5.65)

Income status

Medical aid

1 (Ref.)

0.7285

1 (Ref.)

0.550

Q1

1.04 (0.62, 1.72)

0.88 (0.52, 1.48)

Q2

0.84 (0.49, 1.43)

0.71 (0.41,1.22)

Q3

0.81 (0.48, 1.38)

0.66 (0.38, 1.13)

Q4

1.06 (0.66, 1.72)

0.75 (0.45, 1.24)

Dialysis modality

Preemptive

0.81 (0.56, 1.17)

0.187

0.96 (0.57, 1.60)

0.107

Hemodialysis

1 (Ref.)

 

1 (Ref.)

 

Peritoneal dialysis

1.29 (0.87, 1.92)

 

1.52 (1.02, 2.28)

 

Mixed

0.81 (0.39, 1.68)

 

0.82 (0.39, 1.71)

 

Dialysis duration

< 1 year

1 (Ref.)

0.159

1 (Ref.)

0.809

≥ 1 year

1.25 (0.92, 1.71)

 

1.07 (0.67, 1.71)

 

Desensitization

Yes

1.55 (1.04, 2.30)

0.030

1.64 (1.09, 2.47)

0.018

No

1 (Ref.)

 

1 (Ref.)

 

Induction

Not use

0.86 (0.33, 2.25)

 

1.32 (0.48, 3.60)

 

ATG

1 (Ref.)

0.410

1 (Ref.)

0.580

Basiliximab

1.30 (0.66, 2.56)

 

1.43 (0.72, 2.82)

 

Maintenance

Not use

0.82 (0.26, 2.57)

 

1.01 (0.31, 3.27)

 

Tacrolimus

1 (Ref.)

0.773

1 (Ref.)

0.967

Cyslosporine

0.87 (0.58, 1.32)

 

0.94 (0.62, 1.43)

 
  1. Analysis was performed using univariable and multivariable Cox regression. Model 1: univariable analysis; Model 2: multivariable Cox proportional hazards regression analysis.
  2. ATG anti-thymocyte globulin, CCI Charlson comorbidity index, CI confidence interval, DM diabetes mellitus, HTN hypertension, Income status divided into four income classes by National health insurance premium (Q1: lowest, Q4: highest), KT kidney transplantation, RRT renal replacement therapy, RVO retinal vein occlusion.
Back to article page